Brief: Conmed Q3 Adjusted EPS USD 1.05 Vs. IBES Estimate USD 0.99
30/10/2024 20:05
Oct 30 (Reuters) - Conmed Q3 sales USD 316.701 million vs. IBES estimate USD 318.1 million. * Q3 income from operations USD 65.707 million vs. IBES estimate USD 48.9 million * Q3 pretax profit USD 56.455 million vs. IBES estimate USD 39.6 million * Q3 EPS USD 1.57 * Q3 net income USD 48.984 million * outlook FY adjusted EPS USD 4-4.05
Recent news on Conmed
See all newsBrief: Conmed Enters Agreements To Repurchase 2.25% Convertible Senior Notes Due 2027 On June 3 - SEC Filing
Brief: Conmed Enters First Omnibus Amendment And Increased Facility Activation Notice On May 27, 2026 - SEC Filing
Brief: Conmed Corporation Appoints Celine Martin And Jeff Mirviss To Its Board Of Directors
Medical device maker Conmed raises 2026 organic rev outlook, reaffirms EPS guidance
Brief: Micro-Tech Endoscopy To Acquire Duraclip, Precisor, And Optibite Product Lines From CONMED